Introduction
Fludarabine is a purine analog that has demonstrated significant activity in B-cell malignancies, including CLL and indolent non-Hodgkin's lymphoma. 1 Fludarabine is converted intracellularly into its active metabolite F-ara-ATP, which inhibits DNA as well as RNA synthesis, resulting in induction of growth arrest and apoptosis of malignant B cells. 2 Also, fludarabine has been included in conditioning regimens for stem cell transplantation because of its immunosuppressive effect, 3 although the mechanisms by which fludarabine inhibits T-cell function remain to be fully elucidated.
Nuclear factor kB (NF-kB) is a transcription factor that regulates expression of various genes involved in cell cycle regulation and inhibition of apoptosis and also genes involved in inflammatory and immune responses. [4] [5] [6] We previously showed that inactivation of NF-kB by eight herbal mixture PC-SPES successfully rescued mice from lipopolysaccharide-induced septic shock in association with decreased production of inflammatory cytokines. 7 GVHD is initiated by tissue damage caused by conditioning regimen that consists of chemotherapy and radiotherapy resulting in the release of proinflammatory cytokines, including IL-1b and TNF-a. [8] [9] [10] Donor T-cell recognition of host alloantigens activates T-cells and further stimulates cytokine production. [11] [12] [13] The released cytokines recruit secondary effectors such as macrophages and NK cells to the target organs, especially to the gastrointestinal tract, which damage tissues, resulting in the leakage of endotoxin across damaged mucosal barriers, further exacerbating the cytokine cascade. These events destroy tissues and, in some cases, cause death.
This study explored the medicinal action of fludarabine as an immunosuppressive agent and found that it possessed anti-NF-kB activity.
Materials and methods

Cells
PBMCs were isolated from heparinized blood by density gradient centrifugation using Ficoll-Conray. PBMCs were suspended in standard RPMI 1640 medium (Sigma, St Louis, MO, USA) supplemented with 10% heat-inactivated fetal bovine serum (FBS) and incubated in six-well culture plates (Costar, Corning, NY, USA) for 2 h at 37 1C with 5% CO 2 . The acute lymphoblastic T-cell leukemia Jurkat cells were cultured in standard RPMI 1640 medium (Sigma) supplemented with 10% FBS.
Chemicals
Fludarabine phosphate or cytarabine was provided by Schering AG (Berlin, Germany) or Nihon Shinyaku Co.
Ltd (Tokyo, Japan), respectively. TNF-a was purchased from Sigma Chemical, Co. (St Louis, MO, USA).
Western blot analysis
Western blot analysis was performed as described previously 7 Anti-IkBa (Imgenex, San Diego, CA, USA), anti-phospho-IkBa, anti-cleaved Poly (ADP-ribose) polymerase PARP (Cell Signaling, Beverly, MA, USA), anti-p65 subunit of NF-kB (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and anti-a-tubulin (Santa Cruz Biotechnology) antibodies were used.
Immunocytochemistry
Jurkat cells were cultured either with or without fludarabine (2.5 mM) for 3 h and then exposed to TNF-a (20 ng/ml). After 15 min, the cells were harvested and cytocentrifuge slides were prepared. Anti-p65 (Santa Cruz) and anti-mouse IgG antibodies (Amersham Corp., Arlington Heights, IL, USA) were used for immunocytochemistry. Immune complexes were visualized using the LSAB2 system (Dako Corp., Carpinteria, CA, USA). Sections were counterstained with hematoxylin and mounted.
MTT assays
The effect of fludarabine on proliferation of PBMCs was assessed by measuring the mitochondrial-dependent conversion of the 3-4,5-dimethylithiazol-2-yl)-2,5-diphenyl tetrazolium salt (MTT) (Sigma) to a colored formazan product. PBMCs (4 Â 10 6 /ml) were placed in 96-well plates (Flow Laboratories, Irvine, CA, USA) and cultured under the following conditions in the presence or absence of various concentrations of fludarabine (0.5-5 mM) for 3 days: (1) culture medium alone (control); (2) culture medium plus phytohemagglutinin (5 mg/ml) or TNF-a (20 ng/ml); (3) culture medium plus irradiated (3 Gy) allogenic PBMCs (4 Â 10 6 /ml). All experiments were done in triplicate and repeated at least three times.
Electrophoretic mobility shift assay Electrophoretic mobility shift assay was done as previously described. 7 Briefly, 4 mg of unclear extracts was incubated with 16 fmol of 32 P-end-labeled, NF-kB binding probe. The DNAprotein complex was separated from the free oligonucleotide on a 5% polyacrylamide gel. Gels were dried and exposed to Kodak XAR film (Eastman Kodak, New Haven, CT, USA).
Assessment of apoptosis
TNF-a (20 ng/ml)-stimulated PBMCs (1 Â 10 6 cells/ml) were placed in 12-well plates and cultured with/without fludarabine (0.5-5 mM). After 24 h, apoptosis was evaluated by annexin V staining.
RNA isolation and reverse transcription-polymerase chain reaction RNA isolation and cDNA preparation were performed as described previously. 14 We measured expression of 18S for normalization as previously described.
14 Real-time PCR was carried out by using Power SYBR Green PCR Master Mix (Applied Biosystems, Warrington, UK) as described previously.
14 Primers for PCR are shown in Table 1 . PCR conditions for all genes were as follows: 95 1C initial activation for 10 min followed by 45 cycles of 95 1C for 15 s and 60 1C for 30 s, and fluorescence determination at the melting temperature of the product for 20 s on an ABI PRISM 7000 (Applied Biosystems).
Statistical analysis
To assess the difference between two groups under multiple conditions, one-way followed by Bonferroni's multiple comparison tests was performed using PRISM statistical analysis software (GraphPad Software Inc., San Diego, CA, USA).
Results
Effect of fludarabine on TNF-a-induced phosphorylation and degradation of IkBa and nuclear translocation of NF-kB (p65) in Jurkat cells
In resting T cells, NF-kB proteins are sequestered in the cytoplasm as latent precursors by IkBa. 15 Upon phosphorylation at Ser32 and Ser36 residues, IkBa undergoes degradation by the 26S proteasome, resulting in the release of NF-kB, leading to nuclear translocation and binding to a specific consensus sequence in the DNA. To investigate whether fludarabine inhibits TNF-a-stimulated NF-kB activity in Jurkat cells, control and fludarabine-treated Jurkat cells were exposed to TNF-a (20 ng/ml) for various durations and the kinetics of IkBa phosphorylation and degradation were studied by western blot analysis using cytoplasmic extracts ( Figure 1a ). As shown in Figure 1a , no significant difference in the pattern of IkBa phosphorylation was observed, but the levels of IkBa were higher in fludarabine-treated Jurkat cells than those in control cells, suggesting that fludarabine prevented TNF-a-stimulated degradation of IkBa in Jurkat cells. We next examined the levels of NF-kB in the nuclei of these cells. TNF-a (20 ng/ml, 0-60 min) stimulated the accumulation of NF-kB in the nucleus in both control cells and fludarabine-treated cells; however, the levels of NF-kB were significantly lower in fludarabine-treated cells (Figure 1b) . The ability of fludarabine to inhibit TNF-a-stimulated nuclear translocation of NF-kB was further confirmed by immunocytochemistry (Figure 1c ). On the other hand, another nucleoside analog cytarabine did not affect TNF-a-stimulated nuclear translocation of NF-kB in Jurkat cells (Figure 1c ).
Effect of fludarabine on NF-kB activity in Jurkat cells
We next examined whether fludarabine affected NF-kB activity in Jurkat cells by utilizing electrophoretic mobility Table 1 PCR primers
Fludarabine and GVHD C Nishioka et al shift assay (Figure 2 ). Exposure of Jurkat cells to TNF-a stimulated NF-kB/DNA binding ( Figure 2 ). Pre-incubation of Jurkat cells with fludarabine (2.5 mM, 60 min) disrupted formation of TNF-a-stimulated NF-kB/DNA binding complex ( Figure 2 ). The NF-kB/DNA complex was competed with 100 times molar excess of unlabeled oligonucleotides but not with the same molar excess of mutated oligonucleotides, confirming the specificity of NFkB binding (Figure 2 ).
Fludarabine inhibits proliferation of TNF-a-, PHA-and alloantigen-activated PBMCs NF-kB is activated by extracellular signals, including TNFa 16,17 and PHA, 18 and regulates proliferation of activated T lymphocytes. 18 We therefore examined whether fludarabine affected proliferation of T lymphocytes. Either TNF-a (20 ng/ml) or PHA (5 mg/ml) stimulated proliferation of PBMCs from healthy volunteers (n ¼ 3) 1.25-and 2.5-fold, respectively, on the third day of culture, as measured by MTT assay (Figures 3a and b) . Exposure of these cells to fludarabine (0.5-5 mM) significantly inhibited their proliferation. Likewise, irradiated (3 Gy) allogeneic PBMCs stimulated proliferation of normal PBMCs twofold, and fludarabine effectively blocked alloreactive expansion of PBMCs (Figure 3c ). On the other hand, fludarabine did not affect the viability of resting PBMCs (Figures 3a-c) . Control studies found that cytarabine also inhibited proliferation of TNF-a-or PHA-stimulated but not resting PBMCs (Figures 3d and e) .
Fludarabine induces apoptosis of TNF-a-activated T cells
To investigate the mechanism by which fludarabine inhibits the proliferation of activated PBMCs, we utilized annexin V staining. PBMCs from healthy volunteers were cultured in the presence of TNF-a (20 ng/ml) either with or without fludarabine. After 24 h, apoptosis was assessed by annexin V binding and propidium iodide (PI) staining using FACSCan. As shown in Figure 4 , fludarabine (0.5-5 mM, 24 h) induced approximately 26% of TNF-a-activated PBMCs to become annexin þ /PIÀ, a feature characteristic of apoptosis (Figure 4a ). On the other hand, approximately 14% of control cells became apoptotic after 24 h (Figure 4a ). In addition, western blot analysis showed that exposure of PBMCs to fludarabine (2.5 or 5 mM, 24 h) induced cleavage of PARP in TNF-a-stimulated PBMCs, confirming the ability of fludarabine to induce apoptosis (Figure 4b ). were washed twice with phosphate-buffered saline and exposed to TNF-a (20 ng/ml) for 60 min. Nuclear extracts were prepared and electrophoretic mobility shift assay was performed as described in Materials and methods. The arrow indicates the gel location of NF-kB bound to DNA. WT, wildtype oligonucleotide; mt, mutant oligonucleotide; TNF-a, tumor necrosis factor a; NF-kB, nuclear factor kB. Jurkat cells were cultured either with or without fludarabine (2.5 mM) or cytarabine (2.5 mM) for 3 h. At the end of the treatment, cells were exposed to TNF-a (20 ng/ml) for 15 min. Cells were harvested and cytocentrifuge slides were prepared. Anti-NF-kB and anti-mouse IgG antibodies were used and immune complexes were visualized using the LSAB2 system. Sections were counterstained with hematoxylin. TNF-a, tumor necrosis factor a; NF-kB, nuclear factor kB.
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Effect of fludarabine on TNF-a-stimulated cytokine production Furthermore, we studied whether fludarabine affected TNF-a-stimulated production of proinflammatory cytokines in Jurkat cells and PBMCs. Exposure of Jurkat cells to TNF-a (20 ng/ml, 1 h) profoundly induced expression of IFN-g and IL-2, and pre-incubation of these cells with fludarabine (2.5 mM, 3 h) decreased TNF-a-stimulated expression of either IFN-g and IL-2 by approximately 90 and 80%, respectively, as measured by real-time PCR (Figures 5a and b) . Likewise, fludarabine decreased cytokine-stimulated production of TNF-a in PBMCs (Figures 5c and d) .
Discussion
Fludarabine has been used for treatment of B cell malignancies such as CLL. Fludarabine induced apoptosis of malignant B cells. 19 We have recently shown that fludarabine was also active against T-cell malignancies; fludarabine induced growth arrest and apoptosis of adult T-cell leukemia cells. We found that NF-kB was aberrantly expressed in the nucleus of adult T-cell leukemia cells. Exposure of adult T-cell leukemia cells to fludarabine inhibited nuclear accumulation of NF-kB and downregulated levels of NF-kB-target molecule X-linked inhibitor of apoptosis protein (XIAP) in these cells. 20 Similarly, this study demonstrated that fludarabine blocked TNF-a-induced nuclear translocation of NF-kB in Jurkat T-cells, resulting in inactivation of this prosurvival nuclear transcription factor. As expected, fludarabine inhibited cytokine-and alloantigen-stimulated proliferation of PBMCs in conjunction with decreased production of Th1 cytokines such as IL-2 and IFN-g. IL-2 is secreted by donor CD4 þ T cells in the first several days after the onset of GVHD induction 21 and induces CTL response. Monoclonal antibodies against IL-2 or its receptor were able to prevent GVHD when administered shortly after the infusion of T cells. 22, 23 In addition, both of cyclosporine and FK506, an immunosuppressive agent, dramatically reduced IL-2 production and effectively prevented GVHD. 24 IFN-g is also a crucial cytokine in the second step of the pathophysiology of acute GVHD, which primes mononuclear phagocytes to produce TNF-a and IL-1. High IFN-g levels were associated with acute GVHD, [25] [26] [27] and a large proportion of T-cell clones isolated from GVHD patients produced IFN-g. 28 Thus, inhibition of production of IL-2 and IFN-g may alleviate the severity of acute GVHD.
Another nucleoside analog, cytarabine, also inhibited TNF-a-or PHA-stimulated proliferation of PBMCs ( Figures 3d and e) ; however, cytarabine did not affect TNF-a-induced nuclear translocation of NF-kB in Jurkat cells (Figure 1c ). These observations suggested that inhibition of NF-kB was not universal among nucleoside analogs.
Taken together, fludarabine acts as an immunosuppressive agent via inhibition of NF-kB. Further studies are warranted to evaluate the effect of fludarabine in inflammatory diseases, including GVHD.
